Thermo Fisher Scientific (TMO) has seen a series of ups and downs in recent years. The company declared a quarterly dividend and earnings pointed to moderate buy, according to analysts. Their stock underperformed the market on certain days but has outpaced the market at other times while showcasing strong fundamentals. TMO's earning calls for Q1 2024 and Q4 2023 were held, leading to adjustments in their EPS. The company also warned about the demand in 2024 and navigated economic headwinds with resilient performance in 2023. Their stock has experienced various fluctuations and lowered by significant investors like Boston Partners. Thermo Fisher's intrinsic value and Q4 2024 earnings predictions were worth watching. The Thermo Fisher stock rose by 40%, despite some market disadvantages. The company also reported its first-quarter earnings exceeding expectations and extended the expiration of the tender offer for all outstanding common shares and ADSs of Olink. Moreover, the company stocks fell and rose on several occasions. The introduction of new in-line metrology solution and authorization of $4 billion of share repurchases underline few key developments. Finally, TMO's stock outlook was revised downwards due to market weakening.
Thermo Fisher Scientific TMO News Analytics from Tue, 12 Sep 2023 07:00:00 GMT to Fri, 24 May 2024 23:41:41 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -5
